Events

Precigen discussed the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP).

Moderator: Swayampakula Ramakanth, PhD, Managing Director, Equity Research, H.C. Wainwright
Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen